Cited by 214Neuroinflammation and Neurodegeneration MechanismsPhagocytosis and Immune RegulationAlzheimer's disease research and treatments

The DOI matches its Crossref record; 120 of the 124 references it cites were found in a registry or an index; 1 of the 159 sources its claims cite were checked for support.

Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions

Open access

Published version of a preprint

Abstract

Genome-wide association studies have reported that, amongst other microglial genes, variants in TREM2 can profoundly increase the incidence of developing Alzheimer’s disease (AD). We have investigated the role of TREM2 in primary microglial cultures from wild type mice by using siRNA to decrease Trem2 expression, and in parallel from knock-in mice heterozygous or homozygous for the Trem2 R47H AD risk variant. The prevailing phenotype of Trem2 R47H knock-in mice was decreased expression levels of Trem2 in microglia, which resulted in decreased density of microglia in the hippocampus. Overall, primary microglia with reduced Trem2 expression, either by siRNA or from the R47H knock-in mice, displayed a similar phenotype. Comparison of the effects of decreased Trem2 expression under conditions of lipopolysaccharide (LPS) pro-inflammatory or IL-4 anti-inflammatory stimulation revealed the importance of Trem2 in driving a number of the genes up-regulated in the anti-inflammatory phenotype. RNA-seq analysis showed that IL-4 induced the expression of a program of genes including Arg1 and Ap1b1 in microglia, which showed an attenuated response to IL-4 when Trem2 expression was decreased. Genes showing a similar expression profile to Arg1 were enriched for STAT6 transcription factor recognition elements in their promoter, and Trem2 knockdown decreased levels of STAT6. LPS-induced pro-inflammatory stimulation suppressed Trem2 expression, thus preventing TREM2’s anti-inflammatory drive. Given that anti-inflammatory signaling is associated with tissue repair, understanding the signaling mechanisms downstream of Trem2 in coordinating the pro- and anti-inflammatory balance of microglia, particularly mediating effects of the IL-4-regulated anti-inflammatory pathway, has important implications for fighting neurodegenerative disease.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

Trem2 loss, via siRNA knockdown or the Trem2 R47H knock-in mouse, reduces microglial density/CD68 and impairs IL-4-driven anti-inflammatory gene expression, partly by lowering STAT6. Pro-inflammatory LPS strongly suppresses Trem2 expression, which may limit TREM2’s anti-inflammatory support.

Key findings

  • In 4-month-old homozygous Trem2 R47H KI mice, hippocampal CA1 microglial density was decreased (two-way ANOVA main effect of genotype P < 0.01), CD68-positive microglia were decreased (P < 0.0001), and the proportion of CD68-positive microglia was lower (P < 0.001).
  • Acute Trem2 siRNA (sequence 2, ~80% knockdown; sequence 3, 50–60%) reduced phagocytosis of E. coli by 48.1 ± 9.1%, and Trem2 R47H KI microglia showed more apoptosis (14.6% Annexin V-positive/PI-negative) than WT (7.3%).
  • LPS suppressed Trem2 expression by more than 85% by 24 h; Trem2 knockdown had little additional effect on LPS-induced Tnf or Il1b.
  • IL-4 induced anti-inflammatory genes including Arg1; this response was attenuated with reduced Trem2 (Arg1 one-way ANOVA P = 0.002; WT vs homozygous P = 0.01). Trem2 knockdown decreased total STAT6 protein (two-way ANOVA main effect P < 0.0001) and AKT phosphorylation at Thr308 (P < 0.01) and Ser473 (P < 0.05). RNA-seq found 311 genes decreased and 408 increased in Trem2 R47H KI microglia (DESeq2 FDR < 0.05), and 184 increased/83 decreased with IL-4 (FDR < 0.05).

Methods

  • Primary microglial cultures from WT and Trem2 R47H KI mice were used with siRNA-mediated Trem2 knockdown, LPS (1 μg/ml) or IL-4 (20 ng/ml) treatment, plus hippocampal histology from 4-month-old mice.
  • Main assays included RT-qPCR, RNA-seq, ELISA, western blot, phagocytosis, Annexin V/PI flow cytometry, and immunohistochemistry.
  • RNA-seq analysis used DESeq2 (FDR < 0.05), WGCNA co-expression networks, and i-cisTarget promoter motif enrichment; statistics used ANOVA with Sidak’s post hoc tests, t-tests, and Fisher’s exact test where appropriate.

Limitations

  • The paper states that the Trem2 R47H KI mouse’s reduced Trem2 expression is due to a mouse-specific splicing effect not seen in humans, so the study can conclude little about the R47H mutation itself and mainly models Trem2 loss of function.
  • The paper states that in vitro LPS/IL-4 polarization may not reflect in vivo microglial activation, which involves mixed cues and single-cell heterogeneity; young Trem2 R47H mice also showed no differences in the studied genes in hippocampal homogenates.
  • Evident from the text: findings rely heavily on primary mouse microglial cultures, hippocampal tissue gene expression is diluted by non-microglial cells, and some cell death occurred in culture.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/hmg/ddaa209

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Graphical Abstract
Graphical Abstract CC BY · PubMed Central
Figure 1 Trem2 R47H KI mice (4 months old) showed significant down-regulation of Trem2 expression, and decreased microglia density and CD68 levels in the hippocampus. (A) Gene expression in hippocampal homogenates from homozygous (HO) and heterozygous (HE) Trem2 R47H KI mice relative to Rps28 and then expressed relative to WT within the batch. N = 6–7 mice per group. Data shown as mean ± SEM. One-way ANOVA showed a significant main effect of genotype for Trem2 expression only, and so Sidak’s post hoc tests were used to test pairwise significance between the three genotypes; *P < 0.05, **P < 0.01, ***P < 0.001. (B) Representative images showing AIF1/IBA1 and CD68 immuno-staining of microglia with DAPI in the hippocampal CA1 regions from WT and HO-Trem2 R47H KI mice. The layers from left are SO (stratum oriens), SP (stratum pyramidale), SR (stratum radiatum), and SLM (stratum lacunosum-moleculare). Scale bar: 100 μm. (C) Left: total microglia density in all four CA1 layers was decreased in HO-Trem2 R47H KI mice. Middle: density of CD68 positive microglia decreased in HO-Trem2 R47H KI mice. Right: proportion of CD68 positive microglia was significantly lower in HO-Trem2 R47H KI mice. N = 5–6 mice per group. Data shown as mean ± SEM. Two-way ANOVA with significant main effect of Trem2 genotype indicated with vertical lines, no significant interactions were seen between hippocampal layer and Trem2 genotype; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Figure 1 Trem2 R47H KI mice (4 months old) showed significant down-regulation of Trem2 expression, and decreased microglia density and CD68 levels in the hippocampus. (A) Gene expression in hippocampal homogenates from homozygous (HO) and heterozygous (HE) Trem2 R47H KI mice relative to Rps28 and then expressed relative to WT within the batch. N = 6–7 mice per group. Data shown as mean ± SEM. One-way ANOVA showed a significant main effect of genotype for Trem2 expression only, and so Sidak’s post hoc tests were used to test pairwise significance between the three genotypes; *P < 0.05, **P < 0.01, ***P < 0.001. (B) Representative images showing AIF1/IBA1 and CD68 immuno-staining of microglia with DAPI in the hippocampal CA1 regions from WT and HO-Trem2 R47H KI mice. The layers from left are SO (stratum oriens), SP (stratum pyramidale), SR (stratum radiatum), and SLM (stratum lacunosum-moleculare). Scale bar: 100 μm. (C) Left: total microglia density in all four CA1 layers was decreased in HO-Trem2 R47H KI mice. Middle: density of CD68 positive microglia decreased in HO-Trem2 R47H KI mice. Right: proportion of CD68 positive microglia was significantly lower in HO-Trem2 R47H KI mice. N = 5–6 mice per group. Data shown as mean ± SEM. Two-way ANOVA with significant main effect of Trem2 genotype indicated with vertical lines, no significant interactions were seen between hippocampal layer and Trem2 genotype; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central
Figure 2 The in vitro primary microglial models. Schedule of primary microglia culture from WT or Trem2 R47H KI mice, and treatment with Trem2 siRNA, control non-targeting siRNA, LPS or IL-4.
Figure 2 The in vitro primary microglial models. Schedule of primary microglia culture from WT or Trem2 R47H KI mice, and treatment with Trem2 siRNA, control non-targeting siRNA, LPS or IL-4.CC BY · PubMed Central
Figure 3 LPS suppression of Trem2 in primary microglia. (A) Left: primary microglia stained with an antibody against IBA1 and DAPI. Right: a higher-magnification image showing the morphology of microglia in vitro. (B) Pro- and anti-inflammatory gene expression changes in primary microglia with either LPS or IL-4 treatment. N = 3–6 independent experiments. Data shown as mean ± SEM. One-way ANOVA showed a significant effect of treatment for Tnf, Il1b and Tgfb1. Arg1 was not detected under control conditions, and so Student’s t-test was used to test pairwise significance between 24 and 48 h of IL-4 treatment; *P < 0.05, **P < 0.01, ***P < 0.001. (C) Expression of Trem2. N = 6 mice per genotype. Data shown as mean ± SEM. Two-way ANOVA with significant main effect of both LPS-treatment and genotype, and a significant interaction between treatment and genotype, so Sidak’s post hoc tests were performed to test pairwise significance between the genotypes within a treatment group, marked above individual groups. The interaction reflects a lack of effect of genotype in the LPS treated microglia. ***P < 0.001. (D) ELISA analysis of soluble TREM2 levels in the microglial supernatants. Soluble TREM2 levels were normalized to the expression levels of three housekeeping genes, H3f3b, Arf1 and Rps28 assessed by RT-qPCR. N = 3–4 mice per genotype. Data shown as mean ± SEM. Two-way ANOVA with significant main effect of both LPS-treatment and genotype, and a significant interaction between treatment and genotype (P = 0.0002). Thus Sidak’s post hoc tests were performed to test pairwise significance between the four groups, marked above individual groups. ***P < 0.001, ****P < 0.0001.
Figure 3 LPS suppression of Trem2 in primary microglia. (A) Left: primary microglia stained with an antibody against IBA1 and DAPI. Right: a higher-magnification image showing the morphology of microglia in vitro. (B) Pro- and anti-inflammatory gene expression changes in primary microglia with either LPS or IL-4 treatment. N = 3–6 independent experiments. Data shown as mean ± SEM. One-way ANOVA showed a significant effect of treatment for Tnf, Il1b and Tgfb1. Arg1 was not detected under control conditions, and so Student’s t-test was used to test pairwise significance between 24 and 48 h of IL-4 treatment; *P < 0.05, **P < 0.01, ***P < 0.001. (C) Expression of Trem2. N = 6 mice per genotype. Data shown as mean ± SEM. Two-way ANOVA with significant main effect of both LPS-treatment and genotype, and a significant interaction between treatment and genotype, so Sidak’s post hoc tests were performed to test pairwise significance between the genotypes within a treatment group, marked above individual groups. The interaction reflects a lack of effect of genotype in the LPS treated microglia. ***P < 0.001. (D) ELISA analysis of soluble TREM2 levels in the microglial supernatants. Soluble TREM2 levels were normalized to the expression levels of three housekeeping genes, H3f3b, Arf1 and Rps28 assessed by RT-qPCR. N = 3–4 mice per genotype. Data shown as mean ± SEM. Two-way ANOVA with significant main effect of both LPS-treatment and genotype, and a significant interaction between treatment and genotype (P = 0.0002). Thus Sidak’s post hoc tests were performed to test pairwise significance between the four groups, marked above individual groups. ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central
Figure 4 Trem2 knockdown impairs the IL-4-induced anti-inflammatory response of primary microglia. (A) Trem2 gene expression was not significantly influenced by IL-4 stimulation. (B) Arg1 and Tgfb1 expression, as markers of the anti-inflammatory response, showed significant up-regulation with time after IL-4 application. Particularly, Trem2 knockdown greatly decreased IL-4-induced Arg1 expression compared with negative controls. Gene expression levels were normalized to Rps28 and calculated as fold change relative to the negative control without IL-4 treatment in each individual culture preparation, except for Arg1. Two-way ANOVA with significant main effect of IL-4 incubation time and Trem2 knockdown indicated as horizontal and vertical lines respectively. A significant interaction between IL-4 treatment length and Trem2 knockdown was seen only in Arg1 expression (B), and so Sidak’s post hoc tests were performed to test pairwise significance between the negative siRNA control and Trem2 knockdown at each time-point. (C) Expression of the pro-inflammatory genes (Tnf and Il1b) and other microglial genes. Gene expression levels were normalized to Rps28 and calculated as fold change relative to the negative control without IL-4 treatment in each individual culture preparation. N = 7–9 independent experiments. Data shown as mean ± SEM. Two-way ANOVA; significant main effects of IL-4 treatment time and Trem2-knockdown indicated by horizontal and vertical lines respectively, no significant interactions were seen between IL-4 treatment and Trem2 knockdown; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Figure 4 Trem2 knockdown impairs the IL-4-induced anti-inflammatory response of primary microglia. (A) Trem2 gene expression was not significantly influenced by IL-4 stimulation. (B) Arg1 and Tgfb1 expression, as markers of the anti-inflammatory response, showed significant up-regulation with time after IL-4 application. Particularly, Trem2 knockdown greatly decreased IL-4-induced Arg1 expression compared with negative controls. Gene expression levels were normalized to Rps28 and calculated as fold change relative to the negative control without IL-4 treatment in each individual culture preparation, except for Arg1. Two-way ANOVA with significant main effect of IL-4 incubation time and Trem2 knockdown indicated as horizontal and vertical lines respectively. A significant interaction between IL-4 treatment length and Trem2 knockdown was seen only in Arg1 expression (B), and so Sidak’s post hoc tests were performed to test pairwise significance between the negative siRNA control and Trem2 knockdown at each time-point. (C) Expression of the pro-inflammatory genes (Tnf and Il1b) and other microglial genes. Gene expression levels were normalized to Rps28 and calculated as fold change relative to the negative control without IL-4 treatment in each individual culture preparation. N = 7–9 independent experiments. Data shown as mean ± SEM. Two-way ANOVA; significant main effects of IL-4 treatment time and Trem2-knockdown indicated by horizontal and vertical lines respectively, no significant interactions were seen between IL-4 treatment and Trem2 knockdown; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central
Figure 5 Primary microglia from Trem2 R47H KI mice show decreased Trem2 expression, and an impaired IL-4-induced anti-inflammatory response. (A) Expression of Trem2. (B) Expression of anti-inflammatory markers, Arg1 and Tgf1b. (C) Expression of other microglial genes. Gene expression was normalized to Rps28 and calculated as fold change relative to the WT control without IL-4 treatment. N = 8–15 mice per genotype. Data shown as mean ± SEM. Two-way ANOVA (for all genes except Arg1). Significant main effect of IL-4-treatment and genotype indicated as horizontal and vertical lines respectively, no significant interactions were seen between IL-4-treatment and Trem2 knockdown. Sidak’s post hoc tests were performed to test pairwise significance between the three genotypes within a treatment group. Arg1 was analyzed by one-way ANOVA (P = 0.002) followed by Sidak’s multiple comparisons to test pairwise significance between the three genotypes within a treatment group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Figure 5 Primary microglia from Trem2 R47H KI mice show decreased Trem2 expression, and an impaired IL-4-induced anti-inflammatory response. (A) Expression of Trem2. (B) Expression of anti-inflammatory markers, Arg1 and Tgf1b. (C) Expression of other microglial genes. Gene expression was normalized to Rps28 and calculated as fold change relative to the WT control without IL-4 treatment. N = 8–15 mice per genotype. Data shown as mean ± SEM. Two-way ANOVA (for all genes except Arg1). Significant main effect of IL-4-treatment and genotype indicated as horizontal and vertical lines respectively, no significant interactions were seen between IL-4-treatment and Trem2 knockdown. Sidak’s post hoc tests were performed to test pairwise significance between the three genotypes within a treatment group. Arg1 was analyzed by one-way ANOVA (P = 0.002) followed by Sidak’s multiple comparisons to test pairwise significance between the three genotypes within a treatment group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central
Figure 6 Gene expression profile in primary microglia from Trem2 R47H KI and WT mice with IL-4 treatment by RNA-seq. (A) Volcano plot showing differentially expressed genes for microglia from HO-Trem2 R47H KI versus WT mice by DESeq2 (FDR < 0.05). (B) Biological annotations associated with differentially expressed genes for microglia from HO-Trem2 R47H KI versus WT mice (FDR < 0.05) with enrichment P-values corrected for multiple testing. Vertical dashed line signifies corrected enrichment P = 0.05. (C) Volcano plot showing differentially expressed genes for microglia treated with IL-4 versus untreated by DESeq2 (FDR < 0.05). (D) Biological annotations associated with differentially expressed genes for microglia treated with IL-4 versus untreated (FDR < 0.05) with enrichment P-values corrected for multiple testing. Vertical dashed line signifies corrected enrichment P = 0.05. N = 3 mice per genotype per condition.
Figure 6 Gene expression profile in primary microglia from Trem2 R47H KI and WT mice with IL-4 treatment by RNA-seq. (A) Volcano plot showing differentially expressed genes for microglia from HO-Trem2 R47H KI versus WT mice by DESeq2 (FDR < 0.05). (B) Biological annotations associated with differentially expressed genes for microglia from HO-Trem2 R47H KI versus WT mice (FDR < 0.05) with enrichment P-values corrected for multiple testing. Vertical dashed line signifies corrected enrichment P = 0.05. (C) Volcano plot showing differentially expressed genes for microglia treated with IL-4 versus untreated by DESeq2 (FDR < 0.05). (D) Biological annotations associated with differentially expressed genes for microglia treated with IL-4 versus untreated (FDR < 0.05) with enrichment P-values corrected for multiple testing. Vertical dashed line signifies corrected enrichment P = 0.05. N = 3 mice per genotype per condition.CC BY · PubMed Central
Figure 7 Co-expression genetic networks associated with Trem2 expression and IL-4-treatment. (A) Co-expression network associated with Trem2 expression, using RNA-seq derived gene expression from primary microglia of Trem2 R47H KI and WT mice. Network contains key genes mediating microglial functions, and includes Trem2, Spi1/PU.1, Tyrobp and Stat6. Larger green spheres represent ‘hub’ genes, those showing the greatest number of connections to other genes in the network, which are likely to play important roles in driving microglial functions alongside Trem2. (B) Co-expression network associated with IL-4-treatment, using RNA-seq derived gene expression from primary microglia treated with IL-4 and untreated. Network includes key genes involved in anti-inflammatory processes, such Arg1, Retnla and Chil3. Larger red spheres represent ‘hub’ genes, which are likely to play important roles in driving the microglial response to IL-4. N = 3 mice per genotype per condition.
Figure 7 Co-expression genetic networks associated with Trem2 expression and IL-4-treatment. (A) Co-expression network associated with Trem2 expression, using RNA-seq derived gene expression from primary microglia of Trem2 R47H KI and WT mice. Network contains key genes mediating microglial functions, and includes Trem2, Spi1/PU.1, Tyrobp and Stat6. Larger green spheres represent ‘hub’ genes, those showing the greatest number of connections to other genes in the network, which are likely to play important roles in driving microglial functions alongside Trem2. (B) Co-expression network associated with IL-4-treatment, using RNA-seq derived gene expression from primary microglia treated with IL-4 and untreated. Network includes key genes involved in anti-inflammatory processes, such Arg1, Retnla and Chil3. Larger red spheres represent ‘hub’ genes, which are likely to play important roles in driving the microglial response to IL-4. N = 3 mice per genotype per condition.CC BY · PubMed Central
Figure 8 Cluster of genes showing the highest connectivity to Arg1 from the genetic network associated with IL-4. (A) Heat map showing the genes with the highest connectivity to Arg1 from the co-expression network associated with IL-4 (TOM > 0.465). Selection of genes presented with expression tested by two-way ANOVA, all genes showing a significant main effect of IL-4-treatment and genotype, and a significant interaction. The expression of these genes is represented in primary microglia from HO-Trem2 R47H KI versus WT mice treated with IL-4 or untreated. Colors represent the z-score of the expression level for each gene (red is high expression and blue is low expression). (B) The promoters of genes that show the highest connectivity to Arg1 (TOM > 0.465) contain an enrichment of consensus binding sites for a number of transcription factors including SPI1/PU.1 and STAT6 determined using i-cisTarget. Consensus matrices for SPI1/PU.1 and STAT6 are shown. N = 3 mice per genotype per condition.
Figure 8 Cluster of genes showing the highest connectivity to Arg1 from the genetic network associated with IL-4. (A) Heat map showing the genes with the highest connectivity to Arg1 from the co-expression network associated with IL-4 (TOM > 0.465). Selection of genes presented with expression tested by two-way ANOVA, all genes showing a significant main effect of IL-4-treatment and genotype, and a significant interaction. The expression of these genes is represented in primary microglia from HO-Trem2 R47H KI versus WT mice treated with IL-4 or untreated. Colors represent the z-score of the expression level for each gene (red is high expression and blue is low expression). (B) The promoters of genes that show the highest connectivity to Arg1 (TOM > 0.465) contain an enrichment of consensus binding sites for a number of transcription factors including SPI1/PU.1 and STAT6 determined using i-cisTarget. Consensus matrices for SPI1/PU.1 and STAT6 are shown. N = 3 mice per genotype per condition.CC BY · PubMed Central
Figure 9 Trem2 knockdown resulted in significantly decreased total STAT6 levels and AKT phosphorylation in primary microglia in vitro. (A and B) Total and phosphorylated STAT6 protein levels in primary microglia treated with IL-4 and Trem2 siRNA were analyzed with western blot. N = 4 independent experiments. (C) Stat6 gene expression levels in primary microglia, assessed by RT-qPCR (N = 3 independent experiments). (D and E) Total and phosphorylated (at Thr308 and Ser473) AKT protein levels analyzed by western blot. N = 4 independent experiments. Protein levels were normalized to beta-actin and gene expression was normalized to Rps28. Fold change was calculated relative to the negative control without IL-4 treatment in each individual culture preparation. Note that phosphorylated STAT6 was not detectable under control conditions and so under IL-4 conditions the effect of Trem2 knockdown was calculated as fold change relative to control cells. Data were shown as mean ± SEM. With the exception of phosphorylated STAT6, data were analyzed by two-way ANOVA; significant main effects of IL-4 treatment and Trem2-knockdown indicated by horizontal and vertical lines respectively, no significant interactions were seen between IL-4 treatment and Trem2 knockdown. Phosphorylated STAT6 was analyzed by a one-sample t-test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Figure 9 Trem2 knockdown resulted in significantly decreased total STAT6 levels and AKT phosphorylation in primary microglia in vitro. (A and B) Total and phosphorylated STAT6 protein levels in primary microglia treated with IL-4 and Trem2 siRNA were analyzed with western blot. N = 4 independent experiments. (C) Stat6 gene expression levels in primary microglia, assessed by RT-qPCR (N = 3 independent experiments). (D and E) Total and phosphorylated (at Thr308 and Ser473) AKT protein levels analyzed by western blot. N = 4 independent experiments. Protein levels were normalized to beta-actin and gene expression was normalized to Rps28. Fold change was calculated relative to the negative control without IL-4 treatment in each individual culture preparation. Note that phosphorylated STAT6 was not detectable under control conditions and so under IL-4 conditions the effect of Trem2 knockdown was calculated as fold change relative to control cells. Data were shown as mean ± SEM. With the exception of phosphorylated STAT6, data were analyzed by two-way ANOVA; significant main effects of IL-4 treatment and Trem2-knockdown indicated by horizontal and vertical lines respectively, no significant interactions were seen between IL-4 treatment and Trem2 knockdown. Phosphorylated STAT6 was analyzed by a one-sample t-test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central
Figure 10 Proposed model of the involvement of TREM2 in the IL-4-induced anti-inflammatory response. LPS induces pro-inflammatory activation of microglia, which is accompanied by down-regulated Trem2 expression, and so microglia with reduced TREM2 activity generally show normal activation in response to the pro-inflammatory LPS stimulus. Under non-stimulated conditions, a number of microglial genes are down-regulated when TREM2 activity is decreased, such as Csf1r expression, which may result in the seen reduced survival of microglia. However, IL-4 induces an anti-inflammatory phenotype of microglia. As our data suggest, TREM2 signaling is involved in maintenance of microglial STAT6 levels, which in the IL-4 pathway is phosphorylated and translocates to the nucleus and functions as a key transcription factor for IL-4-induced gene expression changes, such as for Arg1 and Ap1b1. Thus, Trem2 deficiency results in decreased STAT6 levels in microglia, which leads to an impairment of IL-4-induced signaling. TREM2 also regulates the levels of a number of genes that are up-regulated by IL-4 (suppressed by LPS), and considered a component of the transcriptional response to AD-associated pathology, such as Igf1, C1qa, Itgax and Clec7a.
Figure 10 Proposed model of the involvement of TREM2 in the IL-4-induced anti-inflammatory response. LPS induces pro-inflammatory activation of microglia, which is accompanied by down-regulated Trem2 expression, and so microglia with reduced TREM2 activity generally show normal activation in response to the pro-inflammatory LPS stimulus. Under non-stimulated conditions, a number of microglial genes are down-regulated when TREM2 activity is decreased, such as Csf1r expression, which may result in the seen reduced survival of microglia. However, IL-4 induces an anti-inflammatory phenotype of microglia. As our data suggest, TREM2 signaling is involved in maintenance of microglial STAT6 levels, which in the IL-4 pathway is phosphorylated and translocates to the nucleus and functions as a key transcription factor for IL-4-induced gene expression changes, such as for Arg1 and Ap1b1. Thus, Trem2 deficiency results in decreased STAT6 levels in microglia, which leads to an impairment of IL-4-induced signaling. TREM2 also regulates the levels of a number of genes that are up-regulated by IL-4 (suppressed by LPS), and considered a component of the transcriptional response to AD-associated pathology, such as Igf1, C1qa, Itgax and Clec7a.CC BY · PubMed Central

Verification

Claims the paper makes

66 Own result · 56 Not checked yet · 41 Own interpretation · 15 Own method · 3 No basis given · 1 Supported

Verify all 158 references — free account

Show all 100 claims

  • Probably not a substantial claim. 29
  • It may state two separate claims as one. 62
82 of 82
  • The paper relies on this without support.

    The Trem2 R47H knock-in mouse phenotype is effectively a model of down-regulation of TREM2 activity, with changes in microglial number and activation due to a combination of partial Trem2 knockdown and any effect of the R47H mutation.

    “The changes in microglial number and activation in this mouse will thus be a combination of the partial knockdown of Trem2 and any effect of the R47H mutation. Hence this is effectively an in vivo model of down regulation of TREM2 activity, through the combination of these two factors.”
  • The paper relies on this without support.

    Anti-inflammatory signaling is associated with tissue repair.

    “Given that anti-inflammatory signaling is associated with tissue repair, understanding the signaling mechanisms downstream of Trem2 in coordinating the pro- and anti-inflammatory balance of microglia, particularly mediating effects of the IL-4-regulated anti-inflammatory pathway, has important implications for fighting neurodegenerative disease.”
  • The paper relies on this without support.

    The Trem2 decrease in R47H KI mice does not occur in human tissue with this mutation but is a mouse-specific effect related to altered splicing.

    “This does not occur in human tissue with this mutation but appears to be a mouse specific effect related to altered splicing.”
  • The paper relies on this without support.

    ARG1 is an important anti-inflammatory marker induced upon IL-4 stimulation.

    “ARG1 is an important anti-inflammatory marker induced upon IL-4 stimulation.”
  • The paper relies on this without support.

    DUSP4 is a phosphatase for a number of MAPK family members, also known as MKP-2.

    “DUSP4 is a phosphatase for a number of mitogen-activated protein kinase (MAPK) family members, also known as MAPK phosphatase 2 (MKP-2).”
  • The paper relies on this without support.

    Hub genes drive the response of the entire network.

    “Hub genes are those with the highest connectivity within a co-expression network, and are postulated to drive the response of the entire network.”
  • The paper relies on this without support.

    TREM2 variants have high odds ratios for AD risk and R47H is the most common.

    “Of the many genes that have been revealed in GWAS to increase the risk of AD, variants of TREM2 have high odds ratios. The most common of these is the R47H mutation.”
  • The paper relies on this without support.

    The down-regulation of Trem2 in Trem2 R47H KI mice is present throughout life.

    “the down-regulation of Trem2 in these mice is present throughout life”
  • The paper relies on this without support.

    The IGF1 receptor is found largely on neurons.

    “the IGF1 receptor is found largely on neurons”
  • The paper relies on this without support.

    Anti-inflammatory signaling was not studied.

    “However anti-inflammatory signaling was not studied.”
  • The paper relies on this without support.

    The down-regulation of Trem2 expression in Trem2 R47H KI mice is not reflected in humans with the R47H mutation.

    “the down-regulation of Trem2 expression in the Trem2 R47H KI mice which is not reflected in humans with this mutation”
11 of 11

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 124 references

Research works printed but not linked: 1

  1. Benitez, 2013, TREM2 and neurodegenerative disease, N. Engl. J. Med., 369, 1567

Cited by

Sorted by citations

Metadata

Authors
Liu, W., Taso, O., Wang, R., Bayram, S., Graham, A. C., Garcia-Reitboeck, P., Mallach, A., Andrews, W. D., Piers, T. M., Botia, J. A., Pocock, J. M., Cummings, D. M., Hardy, J., Edwards, F. A., & Salih, D. A.
Affiliations
  • University College London (GB)
  • UK Dementia Research Institute (GB)
  • Hitachi Rail Europe Ltd, London EC1N 2PB, UK
  • UCL Queen Square Institute of Neurology (GB)
  • Department of Information and Communications Engineering, Universidad de Murcia, Murcia E-30100, Spain
Corresponding author
Salih, Dervis A
Venue
Human Molecular Genetics
Published
2020-09-22
Volume
29
Issue
19
Pages
3224-3248
ISSN
  • 0964-6906 (ISSN-L)
  • 1460-2083
OpenAlex
W3087562324
Cited by
214
References
124
Citations by year
2026: 35 · 2025: 61 · 2024: 31 · 2023: 33 · 2022: 32 · 2021: 19 · 2020: 2
FWCI
8.41
Type
journal article
Language
en
Open access
Locations
  • Human Molecular Genetics (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • Alzheimer's Research Foundation (ARUK-SRF2013-7, ARUK-PG2019B-018)
  • Biotechnology and Biological Sciences Research Council (BB/M009513/1)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
TREM2, microglia, anti-inflammatory response, pro-inflammatory response, IL-4 signaling, lipopolysaccharide, STAT6, Arg1, microglial density, hippocampus, neuroinflammation, neurodegeneration
MeSH terms
RNA-Seq, Animals, Animals, Newborn, Gene Expression Regulation, Inflammation, Membrane Glycoproteins, Mice, Inbred C57BL, Mutation, Receptors, Immunologic, Microglia, Mice, Knockout, Inflammation Mediators, STAT6 Transcription Factor, Mice, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review